This site already covers astaxanthin and male fertility, where the evidence turns out to be thinner than the marketing. The female side is a genuinely different picture: there are three randomized controlled trials, they were run in fertility clinics on women undergoing assisted reproduction, and they report mixed results: more eggs and embryos in the two IVF trials, no significant difference in pregnancy rate in either, and no change in the symptoms measured in the PCOS trial [1][2][4].
The catch is what the trials measured. Every reported benefit is a laboratory or procedural endpoint. Not one of these trials reports whether more babies were born.
Key Takeaways
- In 50 women with stage III/IV endometriosis undergoing assisted reproduction, 6 mg/day for 12 weeks raised the number of retrieved oocytes (14.60 vs 9.84), mature MII oocytes (10.48 vs 6.72), and high-quality embryos (4.52 vs 2.72) versus placebo [1].
- In 60 poor ovarian responders in the hardest prognostic category, 12 mg/day for eight weeks increased retrieved and mature oocytes and lowered inflammatory markers in both serum and follicular fluid [2].
- A 2025 network meta-analysis of 30 studies and 3,977 patients found astaxanthin alone raised the number of good-quality embryos, but graded that finding as very low certainty [3].
- In women with PCOS, 12 mg/day for eight weeks lowered inflammatory markers but produced no significant change in BMI, hirsutism, hair loss, or menstrual regularity [4].
- No trial in this literature reports live birth rate, which is the outcome fertility patients are actually paying for.
The three trials, and who was in them
These were not general-population studies. Each recruited a specific and difficult clinical group, which is both a strength and a limitation.
The first, published in Frontiers in Endocrinology, enrolled 50 infertile women with stage III or IV endometriosis who were candidates for assisted reproductive techniques. They took 6 mg per day for 12 weeks before their cycle. Blood serum and follicular fluid were sampled before and after [1].
The second, in the Journal of Ovarian Research, enrolled 60 women classified as POSEIDON Group 4, which is the poorest prognosis category in that classification system: over 35 years old, with anti-Mullerian hormone below 1.2 ng/ml or an antral follicle count below 5. They took 12 mg per day for eight weeks alongside a standard gonadotropin-releasing hormone antagonist stimulation protocol [2].
The third, in the Journal of Cellular and Molecular Medicine, enrolled 56 women aged 18 to 40 with polycystic ovary syndrome, at 12 mg per day for eight weeks [4].
All three were randomized and placebo-controlled, and the first two were triple-blind.
What consistently improved
Blood markers of oxidative stress and inflammation improved in these trials, but not every marker moved: follicular-fluid oxidative-stress markers did not differ in the poor-responder trial, and C-reactive protein did not differ in the PCOS trial [2][4].
Research note: The female-infertility network meta-analysis found no supplement, astaxanthin included, significantly linked to miscarriage, though the safety evidence was graded low certainty [3].
In the endometriosis trial, serum total antioxidant capacity and superoxide dismutase rose while malondialdehyde, a lipid peroxidation product, fell. Interleukin-1 beta, interleukin-6, and TNF-alpha all dropped [1]. In the poor-responder trial, the same antioxidant pattern appeared in serum, and interleukin-6, interleukin-8, and vascular endothelial growth factor fell in both serum and follicular fluid. Cell-free DNA, used here as an apoptosis marker, was also lower in follicular fluid [2].
That follicular fluid finding is the more interesting one. Follicular fluid is the immediate environment of the developing egg, so a change measured there is closer to the biology that matters than a change measured in a blood draw. The poor-responder trial found that antioxidant markers in follicular fluid specifically did not differ significantly between groups, even though inflammatory markers did [2]. The picture is not uniformly positive even within a single trial.
The counts that moved, and what they mean
The endometriosis trial reported 14.60 retrieved oocytes on average with astaxanthin versus 9.84 with placebo, 10.48 mature MII oocytes versus 6.72, and 4.52 high-quality embryos versus 2.72 [1]. The poor-responder trial similarly reported significant increases in retrieved and mature oocytes [2].
Astaxanthin raised egg and embryo counts, but the pregnancy rate did not differ
14.60 vs 9.84
Average oocytes retrieved with astaxanthin versus placebo (P = 0.043).
4.52 vs 2.72
Average high-quality embryos with astaxanthin versus placebo (P = 0.024).
44% vs 40%
Clinical pregnancy with astaxanthin versus placebo, not significantly different (two-tailed P = 0.241).
More eggs and embryos in this trial did not become more pregnancies.
Randomized, placebo-controlled trial in 50 infertile women with endometriosis undergoing assisted reproduction. Source: Rostami et al., Frontiers in endocrinology 2023.
Chart: astaxanthinhub.com: Astaxanthin raised egg and embryo counts, but the pregnancy rate did not differ
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
These are real, clinically meaningful-sounding numbers. In IVF, more mature eggs generally means more embryos, and more embryos means more chances at transfer. It is a reasonable proxy.
It is still a proxy. Embryo grade is assigned by visual morphology and correlates imperfectly with implantation. Retrieved oocyte counts vary enormously between cycles in the same patient. And the sample sizes here, 50 and 60, are small enough that a handful of unusually good or bad responders can move a mean substantially.
Pregnancy itself did not differ. In the endometriosis trial, clinical pregnancy was 44% with astaxanthin versus 40% with placebo (P = 0.241), and in the poor-responder trial there were no significant differences in fertilization rate or in chemical or clinical pregnancy rate [1][2].
What the network meta-analysis concluded
In 2025, a Bayesian network meta-analysis in Reproductive Biology and Endocrinology pooled 30 studies covering 3,977 patients to rank nutritional supplements against each other in female infertility [3]. This is the most useful single document in the area, because it places astaxanthin in context rather than in isolation.
Its finding on astaxanthin: taken alone, it produced a notable increase in the number of good-quality embryos, with a mean difference of 1.17 (95% credible interval 0.19 to 2.16). The confidence rating attached to that result, using the CINeMA framework, was very low [3].
Two other results in the same analysis are worth knowing. The combination of probiotics and vitamin D produced the largest increase in clinical pregnancy rate, which is a closer outcome to what patients want than embryo counts. And curcumin alone outperformed astaxanthin on both retrieved oocyte count and fertilization rate, though also at low or very low certainty [3].
So within the supplement field, astaxanthin has a signal, it is not the leading one on the endpoints that matter most, and the evidence quality across the whole category is weak.
What the astaxanthin-only meta-analysis found
A 2024 systematic review and meta-analysis in the Journal of Ovarian Research pooled the clinical trials of oral astaxanthin against placebo or control in assisted reproduction [6]. Only two things reached statistical significance: the oocyte maturation rate (mean difference 8.40, 95% CI 4.57 to 12.23) and total antioxidant capacity in follicular fluid (mean difference 0.04, 95% CI 0.02 to 0.06). Heterogeneity was 0% on both. The other assisted reproduction outcomes, the pregnancy outcomes, and the remaining redox markers did not change significantly [6].
The authors say astaxanthin may improve assisted reproduction outcomes by enhancing oocyte quality and reducing oxidative stress in the reproductive organs, and they also say the evidence is limited by heterogeneity, risk of bias, and small sample sizes [6]. That fits the trial-level picture above: a maturation signal and a better antioxidant environment around the egg, with no demonstrated effect on pregnancy.
The PCOS result is the useful counterexample
The PCOS trial makes the limits of this evidence unusually clear. Astaxanthin reduced the expression of endoplasmic reticulum stress genes in blood cells, lowered TNF-alpha, interleukin-18, interleukin-6, and active caspase-3, and did all this to a statistically significant degree [4].
It also produced no significant improvement in BMI, hirsutism, hair loss, or menstrual cycle regularity. Those four are the symptoms women with PCOS actually present with. C-reactive protein did not change either [4].
A supplement that moves gene expression and cytokines while leaving every clinical symptom unchanged is a demonstration that biomarkers and outcomes are not the same thing. That is the caution to carry into reading the IVF results.
Doses used, and how they compare to the shelf
The trials used 6 mg and 12 mg per day. Unlike much of the astaxanthin literature, these are ordinary consumer doses that map directly onto products people can buy, which makes this one of the few areas where a reader could actually replicate the protocol. Durations were eight and twelve weeks, started before the stimulation cycle rather than during it.
EFSA’s assessment concluded that 8 mg/day from supplements plus a normal diet is safe for adults, so the 12 mg protocols sit slightly above the level that has been formally assessed [5]. Pregnancy is a separate question entirely, and our article on astaxanthin and pregnancy safety covers why the pre-conception and during-pregnancy situations should not be conflated.
Common questions
Will astaxanthin improve my chances of a live birth?
Nobody knows. None of these trials followed participants to delivery. The network meta-analysis found the strongest clinical pregnancy signal for a different intervention entirely, and rated even that as low certainty [3]. Anyone told that astaxanthin raises live birth rates is being told something the literature does not contain.
Do these results apply if I am not doing IVF?
Not directly. All three trials measured outcomes that only exist inside an assisted reproduction cycle: retrieved oocyte counts, MII maturity grades, embryo morphology scores. There is no equivalent evidence for natural conception.
When should it be started relative to a cycle?
The trials started supplementation eight to twelve weeks before retrieval, not during stimulation. That timing is not arbitrary: follicles take roughly three months to develop from the pre-antral stage, so an intervention aimed at egg quality has to be in place well before the cycle begins.
Is this safe to combine with fertility medication?
The poor-responder trial ran astaxanthin alongside a standard GnRH antagonist protocol without reported problems [2]. That is a limited safety observation from 30 treated patients, not a general clearance. This belongs in a conversation with the fertility clinic, which will have its own position on supplements during a cycle, and our drug interactions article covers the broader picture.
References
- Astaxanthin ameliorates inflammation, oxidative stress, and reproductive outcomes in endometriosis patients undergoing assisted reproduction: A randomized, triple-blind placebo-controlled clinical trial. Frontiers in Endocrinology (2023). PMID 37020589
- Astaxanthin improves assisted reproductive technology outcomes in poor ovarian responders through alleviating oxidative stress, inflammation, and apoptosis: a randomized clinical trial. Journal of Ovarian Research (2024). PMID 39482765
- Efficacy and safety of nutritional supplements in female infertility: a network meta-analysis. Reproductive Biology and Endocrinology (2025). PMID 41254684
- Randomized clinical trial of astaxanthin supplement on serum inflammatory markers and ER stress-apoptosis gene expression in PBMCs of women with PCOS. Journal of Cellular and Molecular Medicine (2024). PMID 39036884
- Safety of astaxanthin for its use as a novel food in food supplements. EFSA Journal (2020). PMID 32874213
- Effect of astaxanthin supplementation on female fertility and reproductive outcomes: a systematic review and meta-analysis of clinical and animal studies. Journal of Ovarian Research (2024). PMID 39127677
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
